<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352584</url>
  </required_header>
  <id_info>
    <org_study_id>GC3110A_AD_P3</org_study_id>
    <nct_id>NCT02352584</nct_id>
  </id_info>
  <brief_title>A Multicenter, Double-blind, Parallel Phase III Study</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III Study to Investigate the Efficacy(Immunogenicity) and Safety of GC3110A(Quadrivalent Influenza Vaccine)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III Study to
      Investigate the Efficacy(Immunogenicity) and Safety of GC3110A(Quadrivalent Influenza
      Vaccine) After Intramuscular Administration in Healthy Subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GMT rate of HI(Hemagglutination Inhibition) antibody for each strain</measure>
    <time_frame>Day 21 post vaccination</time_frame>
    <description>GMT (Active comparator) / GMT(Experimental)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited adverse events following vaccination</measure>
    <time_frame>Day0 up to 21 Day post vaccination</time_frame>
    <description>Solicited injection site reactions: Pain, Tenderness, Erythema, Redness, Induration, and Swelling; Solicited systemic reactions: Fever, Sweating, Chill, Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsolicited adverse events following vaccination</measure>
    <time_frame>Day0 up to 21 Day post vaccination</time_frame>
    <description>It can be estimated by Toxicity Grading Scale for healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SCR rate of HI(Hemagglutination Inhibition) antibody for each strain</measure>
    <time_frame>Day 21 post vaccination</time_frame>
    <description>Difference of SCR (Experimental and Active comparator)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SCR rate of HI(Hemagglutination Inhibition) antibody for each strain</measure>
    <time_frame>Day0 up to 21 Day post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPR rate of HI(Hemagglutination Inhibition) antibody</measure>
    <time_frame>Day 21 post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT rate of HI(Hemagglutination Inhibition) antibody for each strain</measure>
    <time_frame>Day 21 post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormalities in physical examination, Vital signs, clinical laboratory tests</measure>
    <time_frame>Day 21 post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAE</measure>
    <time_frame>Day 180 post vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1299</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GC3110A(Quadrivalent)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5ml, intramuscular, a single dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GC Flu (Trivalent)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5ml,intramuscular,a single dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GC3110A(Trivalent)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5ml,intramuscular,a single dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC3110A(Quadrivalent)</intervention_name>
    <description>GC3110A(Quadrivalent), 0.5ml, intramuscular, a single dosing at Day 1</description>
    <arm_group_label>GC3110A(Quadrivalent)</arm_group_label>
    <other_name>GC3110A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC Flu(Trivalent)</intervention_name>
    <description>GC Flu Pre-filled Syringe Inj.(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1</description>
    <arm_group_label>GC Flu (Trivalent)</arm_group_label>
    <other_name>GC Flu Pre-filled Syringe Inj.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC3110A(Trivalent)</intervention_name>
    <description>GC3110A(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1</description>
    <arm_group_label>GC3110A(Trivalent)</arm_group_label>
    <other_name>GC3110A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria: Inclusion Criteria:

          -  Given written informed consent

          -  Healthy Korean adults (age: over 19 )

          -  Korean adults who agree with 21 days follow up after vaccination and good compliance
             to study procedures

          -  Those who are able to comply with the requirements for the study

        Exclusion Criteria:

          -  Inability in written/verbal communication

          -  Subjects who have participated in other interventional study within 30 days

          -  Alcohol or drug abuse within 6 months

          -  Who got the treatment of psychotropic drugs and narcotic analgesic drugs within 6
             months of enrollment

          -  Disorders in immune function

          -  History of Guillain-Barré syndrome

          -  Disease/medications which are likely to cause any severe bleeding

          -  Active infection or experience of fever (&gt;38.0 ℃) within 72 hours following
             vaccination

          -  Oral temperature &gt;38.0 ℃ at the vaccination day

          -  Erythema, tattoo, injury at shoulder (vaccination site)

          -  Hypersensitivity with egg, chicken, or any of the vaccine components, or Neomycin,
             Gentamicin

          -  Influenza vaccination within 6months

          -  Any vaccination within 30 days

          -  Concomitant medications/therapy such as immunosuppressants or immune modifying drugs,
             systemic corticosteroids, immunoglobulins, blood or blood- derived products, or
             anti-cancer chemotherapy or radiation therapy within3 months

          -  Pregnant or breast-feeding women

          -  Clinically significant underlying diseases or medical history at investigator's
             discretion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Jin Su, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Choi Won Seck, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lee Ja Cob</last_name>
    <role>Study Director</role>
    <affiliation>Hallym Univ. Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woo Heong Jung</last_name>
    <role>Study Director</role>
    <affiliation>Hallym Univ. Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wi Sung Heon</last_name>
    <role>Study Director</role>
    <affiliation>St. Vincent's Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeong Suk In</last_name>
    <role>Study Director</role>
    <affiliation>Chonnam Natinal University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim Sin Woo</last_name>
    <role>Study Director</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim Tae Hyung</last_name>
    <role>Study Director</role>
    <affiliation>Soon Chun Hyang Univ. Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <last_update_submitted>October 18, 2015</last_update_submitted>
  <last_update_submitted_qc>October 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>QIV</keyword>
  <keyword>Quadrivalent Influenza Vaccine</keyword>
  <keyword>Influenza vaccine</keyword>
  <keyword>Vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

